FY2025 EPS Estimates for Voyager Therapeutics Cut by Wedbush

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Research analysts at Wedbush cut their FY2025 earnings per share (EPS) estimates for shares of Voyager Therapeutics in a research note issued on Tuesday, February 11th. Wedbush analyst Y. Zhong now forecasts that the company will earn ($1.12) per share for the year, down from their prior forecast of ($1.03). Wedbush currently has a “Outperform” rating and a $9.00 target price on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. Wedbush also issued estimates for Voyager Therapeutics’ Q4 2025 earnings at ($0.29) EPS, FY2026 earnings at ($1.10) EPS, FY2027 earnings at ($0.94) EPS and FY2028 earnings at ($0.87) EPS.

A number of other research firms have also weighed in on VYGR. Citigroup started coverage on Voyager Therapeutics in a report on Monday, December 2nd. They set a “buy” rating and a $12.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a report on Monday, January 27th. Cantor Fitzgerald assumed coverage on shares of Voyager Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating and a $5.73 price target for the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. Finally, StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $15.72.

Voyager Therapeutics Stock Performance

Shares of NASDAQ VYGR opened at $4.38 on Friday. The stock has a fifty day moving average of $5.65 and a 200-day moving average of $6.32. The stock has a market cap of $239.28 million, a PE ratio of 6.17 and a beta of 0.91. Voyager Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.29. The firm had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter in the prior year, the business posted ($0.59) earnings per share.

Institutional Investors Weigh In On Voyager Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its stake in Voyager Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock worth $6,316,000 after purchasing an additional 6,740 shares during the last quarter. FMR LLC increased its holdings in shares of Voyager Therapeutics by 26.9% in the third quarter. FMR LLC now owns 92,498 shares of the company’s stock worth $541,000 after buying an additional 19,622 shares during the period. Barclays PLC lifted its stake in shares of Voyager Therapeutics by 55.8% in the 3rd quarter. Barclays PLC now owns 104,462 shares of the company’s stock valued at $612,000 after acquiring an additional 37,398 shares during the last quarter. Verition Fund Management LLC purchased a new stake in Voyager Therapeutics during the 3rd quarter valued at about $216,000. Finally, Erste Asset Management GmbH bought a new position in Voyager Therapeutics during the 3rd quarter worth approximately $6,192,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now directly owns 112,328 shares in the company, valued at $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 10,778 shares of company stock worth $58,548 over the last 90 days. Corporate insiders own 4.53% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.